Brain leptomeningeal enhancement and cranial nerve enhancement in a pediatric-onset multiple sclerosis patient during fingolimod rebound: A case report
Authors:
- Nikoloz KarazanashviliNKNikoloz Karazanashvili
- Monica M. DiazMDMonica M. Diaz
- Jorge L. AlmodovarJAJorge L. Almodovar
- Bushra JavedBJBushra Javed
- Stephanie IyerSIStephanie Iyer
- Irena Dujmovic BasuroskiIBIrena Dujmovic Basuroski
Open Access
- 1 November 2024
- journal article
- Published by Elsevier in Neuroimmunology Reports
- Vol. 6
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum DisorderPediatric Neurology, 2024
- Frequency and risk factors of rebound after fingolimod discontinuation – A retrospective studyMultiple Sclerosis and Related Disorders, 2023
- The emerging role of FTY720 as a sphingosine 1‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanismsBrain and Behavior, 2021
- Cranial Nerve Enhancement in Multiple Sclerosis Is Associated With Younger Age at Onset and More Severe DiseaseFrontiers in Neurology, 2019
- Fingolimod Rebound: A Review of the Clinical Experience and Management ConsiderationsNeurology and Therapy, 2019
- Different MRI patterns in MS worsening after stopping fingolimodNeurology Neuroimmunology & Neuroinflammation, 2019
- Leptomeningeal inflammation in multiple sclerosis: Insights from animal and human studiesMultiple Sclerosis and Related Disorders, 2018
- The ‘Field Hypothesis’: rebound activity after stopping disease-modifying therapiesMultiple Sclerosis and Related Disorders, 2017
- Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosisNeurology, 2015
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010